---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-158030"
form_type: "8-K"
ticker: "ATOS"
cik: "0001488039"
company_name: "ATOSSA THERAPEUTICS, INC."
filed_at: "2026-04-16T23:59:59+00:00"
generated_at: "2026-05-15T05:46:26.748486+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Atossa settles patent disputes with Intas; Endoxifen patents remain enforceable

## Summary
- Entered Settlement Agreement on April 13, 2026 with Intas Pharmaceuticals and Jina Pharmaceuticals to resolve Endoxifen patent disputes.
- PTAB proceedings will be terminated; U.S. Patent Nos. 11,261,151 and 12,071,391 remain issued and enforceable.
- Mutual covenants prevent parties from challenging each other's specified Endoxifen patents and applications.
- Agreement preserves Atossa's ability to develop and commercialize Z-endoxifen base in oncology, endocrine disorders, and muscular dystrophy.

## SEC filing metadata
- accession: 0001193125-26-158030
- form_type: 8-K
- ticker: ATOS
- cik: 0001488039
- company_name: ATOSSA THERAPEUTICS, INC.
- filed_at: 2026-04-16T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1488039/000119312526158030/0001193125-26-158030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1488039/000119312526158030/d107774d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-158030
- JSON: https://secwatch.observer/filing/0001193125-26-158030.json
- Plain text: https://secwatch.observer/filing/0001193125-26-158030.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.